Allianz Asset Management
BCYC

Allianz Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Allianz Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,600
Closed -$344K – 2220
2024
Q4 		$344K Hold
24,600
– – ﹤0.01% 1969
2024
Q3 		$557K Sell
24,600
-6,000
-20% -$138K ﹤0.01% 1824
2024
Q2 		$619K Hold
30,600
– – ﹤0.01% 1765
2024
Q1 		$762K Hold
30,600
– – ﹤0.01% 1498
2023
Q4 		$553K Buy
30,600
+13,600
+80% +$225K ﹤0.01% 1821
2023
Q3 		$342K Sell
17,000
-3,400
-17% -$77.7K ﹤0.01% 2037
2023
Q2 		$521 Sell
20,400
-700
-3% -$16.3K ﹤0.01% 2085
2023
Q1 		$449K Buy
21,100
+5,900
+39% +$148K ﹤0.01% 1917
2022
Q4 		$450K Hold
15,200
– – ﹤0.01% 1743
2022
Q3 		$354K Sell
15,200
-69,285
-82% -$1.65M ﹤0.01% 1579
2022
Q2 		$1.42M Buy
+84,485
New +$1.78M ﹤0.01% 1548

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Allianz Asset Management's BCYC Position: Q1 2025 in Review

Allianz Asset Management sold out of Bicycle Therapeutics (BCYC) in Q1 2025, closing a stake of 24,600 shares — an estimated $344K sold.

Allianz Asset Management first reported a position in BCYC in Q2 2022 and held it in 11 quarters. The position peaked at $1.42M in Q2 2022. 95 funds tracked by Wall St. Rank hold BCYC as of Q1 2025.

  • Allianz Asset Management reported no remaining Bicycle Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Allianz Asset Management sold 24,600 Bicycle Therapeutics shares in Q1 2025, an estimated $344K.
  • Allianz Asset Management first reported a position in Bicycle Therapeutics in Q2 2022 and held it in 11 quarters.
  • Allianz Asset Management's Bicycle Therapeutics position peaked at $1.42M in Q2 2022.
  • 95 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2025.

Based on Allianz Asset Management's 13F filing for Q1 2025, filed 5 May 2025.